Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (RENSE)

• ClinicalTrials.gov Identifier: NCT01104662
• Recruitment Status: Terminated
• First Posted: April 15, 2010
• Results First Posted: May 13, 2015
• Last Update Posted: September 5, 2018
• Sponsor: Cubist Pharmaceuticals LLC
• Information provided by (Responsible Party): Cubist Pharmaceuticals LLC

Study Description

Brief Summary:

This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of renal impairment (creatinine clearance [CLcr] 30 - 50 milliliters per minute [mL/min] [moderate impairment] and <30 mL/min [severe impairment]) and by type of infection (bacteremia and complicated skin and skin structure infections [cSSSI]) to create 4 cohorts defined as follows:

• Cohort 1: Bacteremia and CLcr <30 mL/min
• Cohort 2: Bacteremia and CLcr 30 - 50 mL/min
• Cohort 3: cSSSI and CLcr <30 mL/min
• Cohort 4: cSSSI and CLcr 30 - 50 mL/min

Participants will be treated and evaluated for safety and microbiological and clinical efficacy in accordance with their type of infection and degree of renal impairment. Peak and trough samples will be collected to assess exposure to daptomycin for participants on Day 1 and following the 5th dose.

Condition or disease	Intervention/treatment	Phase
Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment	Drug: Vancomycin; Drug: Daptomycin; Drug: Semi-Synthetic Penicillin	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 92 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
• Actual Study Start Date: April 19, 2010
• Actual Primary Completion Date: June 12, 2012
• Actual Study Completion Date: June 12, 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: Daptomycin, Bacteremia, Severe Renal Impairment; Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.	Drug: Daptomycin; Other Name: Cubicin
Active Comparator: Vancomycin or SSP, Bacteremia, Severe Renal Impairment; Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.	Drug: Vancomycin; Drug: Semi-Synthetic Penicillin; Other Name: SSP, nafcillin, oxacillin, cloxacillin
Experimental: Daptomycin, Bacteremia, Moderate Renal Impairment; Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.	Drug: Daptomycin; Other Name: Cubicin
Active Comparator: Vancomycin or SSP , Bacteremia, Moderate Renal Impairment; Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.	Drug: Vancomycin; Drug: Semi-Synthetic Penicillin; Other Name: SSP, nafcillin, oxacillin, cloxacillin
Experimental: Daptomycin, cSSSI, Severe Renal Impairment; Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.	Drug: Daptomycin; Other Name: Cubicin
Active Comparator: Vancomycin or SSP , cSSSI, Severe Renal Impairment; Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.	Drug: Vancomycin; Drug: Semi-Synthetic Penicillin; Other Name: SSP, nafcillin, oxacillin, cloxacillin
Experimental: Daptomycin, cSSSI, Moderate Renal Impairment; Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.	Drug: Daptomycin; Other Name: Cubicin
Active Comparator: Vancomycin or SSP , cSSSI, Moderate Renal Impairment; Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.	Drug: Vancomycin; Drug: Semi-Synthetic Penicillin; Other Name: SSP, nafcillin, oxacillin, cloxacillin

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations Through End of Therapy/Early Termination (EOT/ET) [ Time Frame: Baseline through EOT/ET ]
   The number of participants with CPK elevations of >500 units per liter (U/L) above baseline at any time from Day 1 through the EOT/ET visit are presented.

Secondary Outcome Measures :

1. Overall Therapeutic Outcome at Test of Cure (TOC)/Safety Visit [ Time Frame: Baseline through TOC/Safety Visit ]

   Participants were assigned a Sponsor-assessed clinical outcome based on the following definitions at the TOC/Safety visit:

   Failure: Assessed as a failure at any time by the Investigator or received non-study antimicrobial therapy for lack of efficacy or had the primary site of infection removed completely by surgery or underwent surgery to treat the infection >4 days after starting study medication.

   Success: Were not assessed as a failure at any time and were assessed as a cure or improvement by the Investigator at the TOC visit.

   Non-evaluable: Received potentially effective antimicrobial therapy during the study period for reasons other than lack of efficacy or received <4 days of study medication or were not assessed by the Investigator.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Written informed consent
• Male or female ≥18 years of age
• Diagnosis of cSSSI or Staphylococcus aureus (S. aureus) bacteremia
• Renal impairment of CLcr of 30 - 50 mL/min or CLcr <30 mL/min per Cockcroft-Gault equation using actual body weight
• Functioning hemodialysis access and on stable regimen for those receiving dialysis
• In appropriate health for the study with no acute or chronic illnesses that could adversely impact safety or ability to complete the study

Specific inclusion criteria for cSSSI:

• Presence of a wound infection, major abscess, severe carbunculosis, infected ulcers, dialysis access site infection, or other type of infection in presence of complicating factor
• At least 3 of the following symptoms, signs, or laboratory values of a skin infection: elevated temperature; elevated white blood cell (WBC) count; pain; tenderness; swelling; erythema greater than 1 centimeter (cm) beyond wound edge; induration; pus formation
• Evidence of a Gram-positive infecting pathogen as indicated by positive Gram stain or culture obtained within 96 hours prior to study drug administration
• Infection of sufficient severity to require parenteral antimicrobial therapy

Specific inclusion criteria for S. aureus bacteremia:

• Documented S. aureus bacteremia defined as at least one positive blood culture for S. aureus obtained within 96 hours prior to the first dose of study medication

Exclusion Criteria:

• Pregnant or lactating females, or unwilling to practice barrier methods of birth control
• Received an investigational drug (including experimental biologic agents) within 30 days of study entry
• Unable to discontinue use of HMG-CoA reductase inhibitor therapy while on study
• Known allergy or intolerance to daptomycin, penicillin, or vancomycin
• Active intravenous (IV) drug abuse
• Confirmed or suspected osteomyelitis, septic arthritis, meningitis, epidural abscess, intra-abdominal infection, pneumonia, or infective endocarditis
• Required use of non-study systemic antibacterial agent with activity against target pathogen
• History of muscular disease
• Neurological disease except stroke >6 months prior to study entry
• Intramuscular injection within 7 days of study drug administration
• Moribund clinical condition (high likelihood of death during next 3 days)
• Shock or hypotension (supine systolic blood pressure <80 millimeters of mercury [mmHg])
• Body mass index (BMI) <18 or >40 kilograms per meter squared (kg/m^2) [BMI = weight (kg)/height (m^2)]
• Known human immunodeficiency virus (HIV) infection with CD4 count ≤200 cells/millimeter (mm)^3
• Neutropenic participants with an absolute neutrophil count ≤500 cells/mm^3
• Anticipated to develop neutropenia absolute neutrophil count ≤500 due to prior or planned chemotherapy
• Alanine aminotransferase (ALT) value >3 × upper limit of normal (ULN)
• Aspartate aminotransferase (AST) value >3 × ULN
• Total bilirubin values ≥ 1.5 x ULN associated with ALT values >3 x ULN
• Creatine phosphokinase (CPK) value >2 × ULN
• Hemoglobin <8 grams per deciliter (gm/dL)
• Unlikely to comply with study procedures or to return for evaluations
• History of rhabdomyolysis
• Prior enrollment into this study
• Infections caused by Gram-positive pathogens known to be resistant to daptomycin or selected comparator agent

Specific exclusion criteria for cSSSI:

• Minor or superficial skin infections as the primary site of infection
• Cellulitis or erysipelas not associated with complicating factor as primary site of infection
• Perirectal abscess, hidradenitis suppurativa, concomitant gangrene, myositis, multiple infected ulcers at distant sites, necrotizing fasciitis, or infected third-degree burn wounds
• Infections requiring emergency surgery
• Infections suspected or documented to be due exclusively to gram-negative, anaerobic, or fungal organism
• Confirmed or suspected disorder that could interfere with the evaluations (for example, primary skin disorders)
• Use of a topical antibiotic at the site of the infection
• Use of systemic antibacterial therapy for the infection for >24 hours within 48 hours prior to start of study drug unless (a) infecting Gram-positive pathogen resistant to therapy or (b) therapy administered for 3 or more days with worsening or no improvement
• Planned surgical treatment that is considered curative of the infection

Specific exclusion criteria for S. aureus bacteremia:

• Has intravascular foreign material at the time the positive blood culture was drawn (for example., intracardiac pacemaker wires, percutaneous or implanted venous catheters, vascular grafts) unless material removed within 4 days after first dose of study medication or approval of medical monitor (exceptions: vascular stents in place for >6 months, permanent pacemaker attached via epicardial leads, or any dialysis access device unless this material is felt to be infected)
• Prosthetic heart valve
• Cardiac decompensation or valve damage or both with high likelihood of valve surgery in the 3 days after randomization
• Polymicrobial blood infection

Contacts and Locations

Locations

United States, California

Azusa, California, United States

Los Angeles, California, United States

Torrance, California, United States

United States, District of Columbia

Washington, District of Columbia, United States

United States, Georgia

Decatur, Georgia, United States

United States, New Jersey

Somers Point, New Jersey, United States

United States, North Carolina

Winston-Salem, North Carolina, United States

United States, Ohio

Columbus, Ohio, United States

United States, Pennsylvania

West Reading, Pennsylvania, United States

United States, Texas

Mission, Texas, United States

Sponsors and Collaborators

Cubist Pharmaceuticals LLC

Investigators

• Study Director: Ellie Hershberger, Pharm.D.; Cubist Pharmaceuticals LLC

More Information

• Responsible Party: Cubist Pharmaceuticals LLC
• ClinicalTrials.gov Identifier: NCT01104662
• Other Study ID Numbers: 3009-022; DAP-RENSE-08-05 ( Other Identifier: Cubist Study Number )
• First Posted: April 15, 2010
• Results First Posted: May 13, 2015
• Last Update Posted: September 5, 2018
• Last Verified: August 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
• URL: http://engagezone.msd.com/ds_documentation.php

Additional relevant MeSH terms:

Infections; Communicable Diseases; Bacteremia; Skin Diseases, Bacterial; Renal Insufficiency; Disease Attributes; Pathologic Processes; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Skin Diseases, Infectious; Skin Diseases; Vancomycin; Daptomycin; Penicillins; Cloxacillin; Oxacillin; Nafcillin; Anti-Bacterial Agents; Anti-Infective Agents